CA1207105A - Arterial graft prosthesis - Google Patents
Arterial graft prosthesisInfo
- Publication number
- CA1207105A CA1207105A CA000396176A CA396176A CA1207105A CA 1207105 A CA1207105 A CA 1207105A CA 000396176 A CA000396176 A CA 000396176A CA 396176 A CA396176 A CA 396176A CA 1207105 A CA1207105 A CA 1207105A
- Authority
- CA
- Canada
- Prior art keywords
- zone
- elastomer
- arterial graft
- graft prosthesis
- prosthesis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000463 material Substances 0.000 claims abstract description 33
- 239000007787 solid Substances 0.000 claims abstract description 31
- 239000008280 blood Substances 0.000 claims abstract description 30
- 210000004369 blood Anatomy 0.000 claims abstract description 30
- 229920002635 polyurethane Polymers 0.000 claims abstract description 23
- 239000004814 polyurethane Substances 0.000 claims abstract description 23
- 229920001971 elastomer Polymers 0.000 claims description 64
- 239000000806 elastomer Substances 0.000 claims description 64
- 239000011148 porous material Substances 0.000 claims description 19
- 230000003014 reinforcing effect Effects 0.000 claims description 14
- 230000002209 hydrophobic effect Effects 0.000 claims description 6
- 239000004019 antithrombin Substances 0.000 claims description 2
- 229920001169 thermoplastic Polymers 0.000 claims 1
- 239000004416 thermosoftening plastic Substances 0.000 claims 1
- 230000002787 reinforcement Effects 0.000 abstract description 21
- 210000001367 artery Anatomy 0.000 description 31
- 238000010276 construction Methods 0.000 description 10
- 239000002245 particle Substances 0.000 description 7
- 229920003023 plastic Polymers 0.000 description 6
- 239000004033 plastic Substances 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 3
- 230000003190 augmentative effect Effects 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- CWEFIMQKSZFZNY-UHFFFAOYSA-N pentyl 2-[4-[[4-[4-[[4-[[4-(pentoxycarbonylamino)phenyl]methyl]phenyl]carbamoyloxy]butoxycarbonylamino]phenyl]methyl]phenyl]acetate Chemical compound C1=CC(CC(=O)OCCCCC)=CC=C1CC(C=C1)=CC=C1NC(=O)OCCCCOC(=O)NC(C=C1)=CC=C1CC1=CC=C(NC(=O)OCCCCC)C=C1 CWEFIMQKSZFZNY-UHFFFAOYSA-N 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000011800 void material Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229920004934 Dacron® Polymers 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000013536 elastomeric material Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000005661 hydrophobic surface Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000011295 pitch Substances 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 239000004753 textile Substances 0.000 description 2
- 230000008467 tissue growth Effects 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 239000004604 Blowing Agent Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000958041 Homo sapiens Musculin Proteins 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 239000012237 artificial material Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 102000046949 human MSC Human genes 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- GWUSZQUVEVMBPI-UHFFFAOYSA-N nimetazepam Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1 GWUSZQUVEVMBPI-UHFFFAOYSA-N 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 description 1
- 239000012779 reinforcing material Substances 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
- A61F2/07—Stent-grafts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/507—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials for artificial blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/88—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure the wire-like elements formed as helical or spiral coils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/89—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure the wire-like elements comprising two or more adjacent rings flexibly connected by separate members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
- A61F2/07—Stent-grafts
- A61F2002/072—Encapsulated stents, e.g. wire or whole stent embedded in lining
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2002/826—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents more than one stent being applied sequentially
Abstract
ABSTRACT
An arterial graft prosthesis comprises a first interior zone of a solid, segmented polyether-polyurethane material surrounded by a second zone of a porous, segmented polyether-polyurethane and a third zone immediately surrounding said second zone and of a solid, segmented polyether-polyurethane. The interior zone may have a lining or blood interface of a microporous zone of segmented polyether-polyurethane, and the exterior, third zone may be surrounded by a tissue interface of a microporous zone of segmented polyether-polyurethane. In some instances the exterior may be confined by a tube of substantially non-stretchable netting fastened in place at chosen, spaced intervals or other formsof reinforcement may be employed. Other materials can be used.
An arterial graft prosthesis comprises a first interior zone of a solid, segmented polyether-polyurethane material surrounded by a second zone of a porous, segmented polyether-polyurethane and a third zone immediately surrounding said second zone and of a solid, segmented polyether-polyurethane. The interior zone may have a lining or blood interface of a microporous zone of segmented polyether-polyurethane, and the exterior, third zone may be surrounded by a tissue interface of a microporous zone of segmented polyether-polyurethane. In some instances the exterior may be confined by a tube of substantially non-stretchable netting fastened in place at chosen, spaced intervals or other formsof reinforcement may be employed. Other materials can be used.
Description
~Z07105 ARTERIAL GRAFT PROSTHESIS
Prosthetic arterial grafts have been available to the medical profession for thirty years or more. I lo.~ r, during that thirty years the development of suchgrafts have been limited to those formed of textile fabrics and of semi-rigid 5 plas$ics such as Teflor*which have been made somewhat flexible by distension or stretching so that microscopic pores are produced which, although too small to permit the passage of blood, do permit some degree of flexibi~ity. Such porositydoes allow such grafts to eventually leak under certain conditions. Textile arterial grafts are generally a single tubular structure. Arterial graft prosLheses 10 of illetc.lled, semi-rigid plastics have been made of multiple parts or tubes but the resultant structure has not been homogeneous or attached so that it may be separable under normal conditions of use such as during the suturing of the graft in place.
In the development of an arterial graft ploslhesis should have static and dynamic lS elastic moduli and pressure distension in both the radial and axial directions which closely match those for normal human arteries of the same diameter.
Moreover~ ~he waJI thickness should be very close to that of the human artery and should resist kinking when bent as well as do natural arteries. The prosthesis should have uniform homogeneous physical properties fully along its length so 2Q that the surgeon may cut any length he desires. Moreover, it should be easilysutured with the same needle penetration force and suture pull through force as is required with natural arteries. The suture should not pull out nor tear to any greater extent n~r with any less ~orce than with the na~ural artery. The prosthesis should be impervious to blood not only along the major portion of its25 length but also where the customary needle holes are placed during suturing.
This~ particu~arly, has not bee possible with graft prosthesis of the prior art in which leaking at suture points usually exists until a thrombus is formed.
Moreover, the prosthesis should inhioit tissue growth throughout the graft * Trade Mark .-. ~' ~Z~'7~0S
structure which would result in the stiffening of the graft itself. It should becompatible with blood and tissue and should also provide attachment to external tissues for fixation and avoidance of trapped fluids inside a loose tissue capsule.
The graft should remain patent and unobstructed indefinitely without any 5 inherent clot or generation of thrombo-emboli. These objectives have not been met by the arterial graft prosthesis of the prior art.
A representative arterial graft prosthesis in accordance with the invention comprises at least two concentric zones of elastomer material homogeneously joined together to form a single tube with the elastomer in one of the zones 10 being porous. Ln o~her embodiments such a tube is, in turn, surrounded by a third zone of a solid, segmented elastomer. Also, the interior surface or the exteriorsurface, or both, of the mentioned three-zone tube may also be augmented from time to time and for different conditions.
FIGURE 1 ls a longitudinal, diametrical cross section of a composite arterial 15 graft showing not only the three mentioned ~ones of segmented elastomer but also an interior and exterior lining zone and an exterior confining reinforcement.
FIGUR~ 2 is a view comparable to FIGURE 1 but in which the confining reinforcement, instead of bein~ external and of woven material, is internal and of a helically wrapped thread.
20 FIGURE 3 is a view comparable to FIGURE 1 but without reinforcement.
FIGURE 4 is another view comparable ~o FIGURE 2 but with some small variations.
FIGURE 5 is a longitudinal, diametrical cross section showing a preferred variation having reinforcement in the porous zone.
25 FIGURE 6 shows a preferred embodiment particularly adapted to small diameter grafts.
FIGURE 7 is a view comparable to FIGURE 1 but having a corrugated internal construction .
FIGURE 8 is a view like FIGURE 7 but in which the entire construction is 30 corrugated lZ~ LO~
FIGURE 9 is a view like FIGURE 7 but in which the exterior is corrugated, while the interior is smooth.
FIGURE 10 is another variation showing reinforcement in the form of hoops which are helical and augmented.
5 FIGURE 11 is an end view of the structure of FIGURE 10 with a portion broken away to show the interior construction.
FIGURE 12 is an isometric view showing an embodiment with hoop reinforce-ments.
FIGU~E 13 is a view like FlGURE 12 with different shaped hoops.
10 FIGURE 14 is a view like FIGllRE 1 with a plurality of internal concentric helical reinforcements.
FIGURE 15 is a view like FI~URE 14 in which the reinforcements are concentric hoops rather than helical.
~IGURE 16 is like the FIGURE 14 version~ but the reinforcement is by a single 15 row of rings rather than by a pair of coaxial helices.
FIGURE 17 is like the FIGURE 16 arrangement but the reinforcing rings are of a flat stock rather than round stock.
~Ihile the drawings herein show the various zones of the arterial graft separated by solid lines, it must be recognized that the zones are homogeneously attached 20 to each other while the substance of at least one of the zones is in a liquid or semi-liquid state. The various zones are formed of the same general material such as polyurethane. The polyurethane is dissolved in a solvent and applied as a viscous liquid. The solvent within the liquid penetrates the surfaces of the attached zones and provides for homogeneous mixing of the polymers and 25 adhesion as if it were of one material. Consequently, the interface between zones has some finite dimension of thickness not shown in the drawing and havinga composition which is a blend of the two adjacent zones.
In the representative version of the arterial graft shown in FIGURE 1, there is provided, symmetrical with a center line 5, an inside tubular zone 6. This is a lZ~7105 generally impervious zone of a segmented polyether-polyurethane material which is continuous and is largely a barrier to the various liquid materials with which it is normally associated. The zone 6 is approvimately one to six mils in radial thickness and is generally a radial bar to the blood which flows through the 5 graft under normal pressures and actions.
Directly surrounding the tubular zone 6 there is an intermediate zone 7 also fundamentally of polyether-polyurethane but preferably of somewhat greater thickness -- generally from 10 to 80 mils. The zone 7 is of a porous nature, bein~ from thirty percent to ninety per cent void or open volume. The void 10 volume may be of uniformly sized and distributed pores with the pores 8 ranging from one to one undred fifty microns in size.
Usually, the intermediate zone 7 is directly surrounded by an ecompassing or outward zone 9. This also is of a segmented polyether-polyurethane material corresponding to that in the zone 6 and having a lack of pores or orifices, being 15 continuous like the zone 6 and so distinguished from the porous zone 7. The radial dimension of the zone 9 is from one to six mils~ The portions of this form of substitute blood vessel thus far described are all made of segmented polyether-polyurethane zones of different sizes and with the central zone, only,~ontaining a number of cells or spaces or voids.
20 Reference herein is made primarily to the zones being of a segmented polyether-polyurethane material, and that has proved to be most satisfactory in practice. 1~ must be noted, however, that of the numerous elastomers available (Ior example, silicone rubber) in various instances there may be used elastomersthat are not segmented and are not polyesters nor polyethers. hluch of ~he
Prosthetic arterial grafts have been available to the medical profession for thirty years or more. I lo.~ r, during that thirty years the development of suchgrafts have been limited to those formed of textile fabrics and of semi-rigid 5 plas$ics such as Teflor*which have been made somewhat flexible by distension or stretching so that microscopic pores are produced which, although too small to permit the passage of blood, do permit some degree of flexibi~ity. Such porositydoes allow such grafts to eventually leak under certain conditions. Textile arterial grafts are generally a single tubular structure. Arterial graft prosLheses 10 of illetc.lled, semi-rigid plastics have been made of multiple parts or tubes but the resultant structure has not been homogeneous or attached so that it may be separable under normal conditions of use such as during the suturing of the graft in place.
In the development of an arterial graft ploslhesis should have static and dynamic lS elastic moduli and pressure distension in both the radial and axial directions which closely match those for normal human arteries of the same diameter.
Moreover~ ~he waJI thickness should be very close to that of the human artery and should resist kinking when bent as well as do natural arteries. The prosthesis should have uniform homogeneous physical properties fully along its length so 2Q that the surgeon may cut any length he desires. Moreover, it should be easilysutured with the same needle penetration force and suture pull through force as is required with natural arteries. The suture should not pull out nor tear to any greater extent n~r with any less ~orce than with the na~ural artery. The prosthesis should be impervious to blood not only along the major portion of its25 length but also where the customary needle holes are placed during suturing.
This~ particu~arly, has not bee possible with graft prosthesis of the prior art in which leaking at suture points usually exists until a thrombus is formed.
Moreover, the prosthesis should inhioit tissue growth throughout the graft * Trade Mark .-. ~' ~Z~'7~0S
structure which would result in the stiffening of the graft itself. It should becompatible with blood and tissue and should also provide attachment to external tissues for fixation and avoidance of trapped fluids inside a loose tissue capsule.
The graft should remain patent and unobstructed indefinitely without any 5 inherent clot or generation of thrombo-emboli. These objectives have not been met by the arterial graft prosthesis of the prior art.
A representative arterial graft prosthesis in accordance with the invention comprises at least two concentric zones of elastomer material homogeneously joined together to form a single tube with the elastomer in one of the zones 10 being porous. Ln o~her embodiments such a tube is, in turn, surrounded by a third zone of a solid, segmented elastomer. Also, the interior surface or the exteriorsurface, or both, of the mentioned three-zone tube may also be augmented from time to time and for different conditions.
FIGURE 1 ls a longitudinal, diametrical cross section of a composite arterial 15 graft showing not only the three mentioned ~ones of segmented elastomer but also an interior and exterior lining zone and an exterior confining reinforcement.
FIGUR~ 2 is a view comparable to FIGURE 1 but in which the confining reinforcement, instead of bein~ external and of woven material, is internal and of a helically wrapped thread.
20 FIGURE 3 is a view comparable to FIGURE 1 but without reinforcement.
FIGURE 4 is another view comparable ~o FIGURE 2 but with some small variations.
FIGURE 5 is a longitudinal, diametrical cross section showing a preferred variation having reinforcement in the porous zone.
25 FIGURE 6 shows a preferred embodiment particularly adapted to small diameter grafts.
FIGURE 7 is a view comparable to FIGURE 1 but having a corrugated internal construction .
FIGURE 8 is a view like FIGURE 7 but in which the entire construction is 30 corrugated lZ~ LO~
FIGURE 9 is a view like FIGURE 7 but in which the exterior is corrugated, while the interior is smooth.
FIGURE 10 is another variation showing reinforcement in the form of hoops which are helical and augmented.
5 FIGURE 11 is an end view of the structure of FIGURE 10 with a portion broken away to show the interior construction.
FIGURE 12 is an isometric view showing an embodiment with hoop reinforce-ments.
FIGU~E 13 is a view like FlGURE 12 with different shaped hoops.
10 FIGURE 14 is a view like FIGllRE 1 with a plurality of internal concentric helical reinforcements.
FIGURE 15 is a view like FI~URE 14 in which the reinforcements are concentric hoops rather than helical.
~IGURE 16 is like the FIGURE 14 version~ but the reinforcement is by a single 15 row of rings rather than by a pair of coaxial helices.
FIGURE 17 is like the FIGURE 16 arrangement but the reinforcing rings are of a flat stock rather than round stock.
~Ihile the drawings herein show the various zones of the arterial graft separated by solid lines, it must be recognized that the zones are homogeneously attached 20 to each other while the substance of at least one of the zones is in a liquid or semi-liquid state. The various zones are formed of the same general material such as polyurethane. The polyurethane is dissolved in a solvent and applied as a viscous liquid. The solvent within the liquid penetrates the surfaces of the attached zones and provides for homogeneous mixing of the polymers and 25 adhesion as if it were of one material. Consequently, the interface between zones has some finite dimension of thickness not shown in the drawing and havinga composition which is a blend of the two adjacent zones.
In the representative version of the arterial graft shown in FIGURE 1, there is provided, symmetrical with a center line 5, an inside tubular zone 6. This is a lZ~7105 generally impervious zone of a segmented polyether-polyurethane material which is continuous and is largely a barrier to the various liquid materials with which it is normally associated. The zone 6 is approvimately one to six mils in radial thickness and is generally a radial bar to the blood which flows through the 5 graft under normal pressures and actions.
Directly surrounding the tubular zone 6 there is an intermediate zone 7 also fundamentally of polyether-polyurethane but preferably of somewhat greater thickness -- generally from 10 to 80 mils. The zone 7 is of a porous nature, bein~ from thirty percent to ninety per cent void or open volume. The void 10 volume may be of uniformly sized and distributed pores with the pores 8 ranging from one to one undred fifty microns in size.
Usually, the intermediate zone 7 is directly surrounded by an ecompassing or outward zone 9. This also is of a segmented polyether-polyurethane material corresponding to that in the zone 6 and having a lack of pores or orifices, being 15 continuous like the zone 6 and so distinguished from the porous zone 7. The radial dimension of the zone 9 is from one to six mils~ The portions of this form of substitute blood vessel thus far described are all made of segmented polyether-polyurethane zones of different sizes and with the central zone, only,~ontaining a number of cells or spaces or voids.
20 Reference herein is made primarily to the zones being of a segmented polyether-polyurethane material, and that has proved to be most satisfactory in practice. 1~ must be noted, however, that of the numerous elastomers available (Ior example, silicone rubber) in various instances there may be used elastomersthat are not segmented and are not polyesters nor polyethers. hluch of ~he
2~ actual work herein has been done with a segmented polyether-polyurethane ma~erial, spe~ifically such material sold under the trademark "Biomer", and so, for convenience, those materials are referred to herein. Yet, it must be recognized that comparable and substitute materials may be used or may become available.
30 Construction of an arterial graft prosthesis, as defined herein, results in static and dynamic moduli and pressure distortions in both radial and axial directions closely to match such distensions of normal human arteries of comparable diameter. Consequently, even after clamping, the prosthesis of the present invention, unlike the prior art prostheses, recover in the same manner as do 35 natural arteries. Also, $he wall thickness used is very close to that of human 1~7~05 arteries of a comparable diameter. ~urthermore, these prostheses, when formed, resist kinking when bent as well as the normal, natural arteries. There are uniform, homogeneous physical properties along the entire length of the insert or graft, so that the surgeon can cut an insert to any length he desires 5 with uniform results.
The prostheses defined suture as easily and with substantially the same needle penetration force and suture pull through force as l the case of natural arteries.
Also, sutures made in the prostheses do not pull out or tear to any greater extent or with any less force than those in a natural artery. The grafts defined, when 10 formed, are impervious or leak tight to the circulating blood. The customary needle holes are subs~antially immediately self-closing, so that they do not leak any contained blood. Furthermore, the prostheses inhibit tissue growth throug-hout the graft structure and so prevent a resultant sti~fening of the ~raft. They readily provide appropriate fixation for external tissue attachment and ready 15 avoidance of trapped fluids inside the tissue capsule. The prostheses are quite compatible with the customary blood and adjacent tissues. Also, the formed, indicated prostheses generally remain open and unobstructed indefinitely and without any adherent clot or the generation of internal thrombo-emboli. The net result is that the described prostheses afford an arterial replacement which is in 2~ most respects virtually indistinguishable from the original native artery.
In addition to the zones 6, 7 and 9, the embodiment of FIGURE 1 also includes a microporous blood interface 10. In an arterial graft of appro3~imately six millimeter internal diameter or more~ the blood ;nterface 10 may comprise a zone of "Biomer", having interior pores of a diameter and depth ranging from 25 five to one hundred microns, approximately. Preferably, the microporous tissue is trea.ted to be hydrophilic or hydrophobic, for instance, by subjection to known gas plasma or electrical discharge methods. The so-trea~ed microporous tissue interface is effective as an anchoring substrate for a developing pseudointirna which form~ blood constituents. This pseudointima is a ~issue layer which must 30 adhere to the blood interface and remains quite thin. If desired, the hydrophilic or hydrophobic microporous blood interface may be coated with an antithrombin such as albumin, gelatin, glycoproteins, bonded heparin or comparable material to prevent or to diminish any early thrombus formation. Such initial coatings, in use, may gradually be replaced with the developing pseudointima as described.
35 About the outside of the graft is an adheran~ surrounding tissue interface 11.
The material of the interface 11, like the blood interface 10, may also be a ~2~710S
microporous "Biomer" but ~ith slightly larger pores -- in the range of thirty toone hundred fifty microns. The surface of this interface may also and similarly be made hydrophilic or hydrophobic.
Particularly for the porous core 7 but also for the interfaces 10 and 11, the 5 homogeneous pores are initially formed by the use of partlculates such as salt(NaCI) or sodium bicarbonate, which is ultimately largely removed by diffusion in a water or very dilute acid bath. The sodium bicarbonate also acts as a blowing agent in that the CO2 is released and thus decreases the amount of salt to be removed from the core. The particulates utilized for this purpose are screened lû to afford a very narrow range of sizes, so that the pore sizes themselves areconfined to a very narrow range. The result is a porous of foam-like structure containing closed-cell or open-cell voids with a substantially reduced general density.
The salt particles, for example, and the "aiomer" or core solution are completely 15 and homo~eneously mixed to form a slurry. Different slurries, with or withoutsalt particles, are then used to form the various zones on a mandrel. The first slurry (with salt or sodium bicarbonate particle size to produce pores of frorn five to one hundred microns) is applied directly to the mandrel by dipping, coating or doctoring to form the zone 10. This is followed by an unsalted 20 solution to form the zone 6 and the sequence is continual until the entire graft is fabricated. The coatings on the mandrel are then thoroughly dried to remove the solvent and then the salt or bicarbonate particles are removed in a water bath at about 60 C. There are water-filled voids so created by the dissolution and diffusion OI the salt particles. The particle size and concentratlon of particles 25 are arranged to control the density or porosity and pore size. For example, sodium chloride part;cles of ~bout ~ifty micron average size are used for the zone 7 and the optimum range is within about one to one hundred fifty microns.
The total void volume is about fifty per cent of the total layer volume, the range being from about thirty percent to ninety percen~.
30 The result of the foregoing is the production of a readily patent and clinically superior tubular graft which simulates very closely the properties of a natural artery. This provides that the artificial graft can be sutured to adjacent arteries very much as though a natural artery were utilized. The dimensional and distensional simulat;on by the artificial material to the natural material reduces ~5 or eliminates sutureline disc~ntinuities and obstructions. Furthermore, grafts of ~;~871~)5 the present prostheses behave very much like the natural artery, so that the surgeon's sl;ill and experience are fully utilized. Also, the grafts of .n~ presen.
prostheses provide the same suturability, feedom from kinking, clamping charac-teristics, impermeability, biocompatability, antithrombogenicity, patency, and 5 other advantages of natural arterial material.
Although the present artificial construction has two or often three zones, nevertheless the several zones allow Eor the provision of individual or separatecomponent characteristics, preferably all based on the polyether-polyurethane structure.
10 In some instances, it is desirable to surround the exterior o the artificial artery so provided with a confining netting 12 of "Dacron" or the like or a circumferen-tial winding of 2 suitable filament 13 ~see FIGURE 2) which may be formed of "Dacron", solid elastomer, wire or the like. When external, as in FIGURE 11 thisreinforcement is customarily adhesively affixed at spaced intervals and loosely 1~ surrounds the remainder o~ the artificial artery. The netting comes into playprimarily only in the event there is a substantial expansion of the artery. The netting confines the amount of such expansion to preclude undue stretching and thinning of the artery walls.
As an alternative to the attachment of the reinforcing material to the outer 20 zone of the prosthesis, as shown in FIGURE 1, it rnay be formed within one ormore of the zones of elastomer as particularly shown in FlGURE 2, the purpose here also being to preclude undue expansion of the artificial arter~.
Clinical experience has indicated that an artificial artery constructed as described herein and particularly fabricated primarily of polyether-polyurethane25 is virtually indistinguishable from the naturally occurring artery which it replaces and afford a long term, effective and trouble free substitute for the originally occurring, natural artery.
The alternative embodiment of FIGURE 2 differs from that of FiGURE 1 not only in the type of reinfoFcing material, but also in that the tissue interface 11 is 30 eliminated.
Another modified graft as shown in FIGURE 3 is a section 21 acting as an artery generally symmetrical about a longitudinal axis 22 and particularly inclusive ofan inside zone 23 of relatively solid polyether-polyurethane, preferably of * Trade Mark ~2~'7~0S
segmented polyether-polyurethane. The zone 23 is arranged symmetrically about the axis 22 or approximately SQ and on its inner surface is covered particularlywith an inner coat 24 of a micro porous blood interface of polyether-polyurethane. The pores in the interface coat 24 are in the range of five to one5 hundred microns in size and depth, and the coat itself is treated primarily to be hydrophilic.
The inside zone 23 and the inside coat 24 line a tubular zone or body 26 of a porous, segmented polyether-polyurethane having pores of about one to one hundred fifty microns in size. The pores are sufficient in number and disposition 10 to allow from a~out thirty per cent to ninety per cent of the zone 26 to consist of pores.
Around the tubular body 26 there is a further zone ~7 of relatively solid polyether-polyurethane about one to six mils thick. Finally~ surrounding the zone 27 there is a generally exposed microporous tissue interface 2~ comprised 15 of polyether-polyurethane having pores of about thirty to one hundred fifty microns in size and depth. This e3~terior interface 28 likewise is treated to behydrophilic.
It is found that with these materials and this general arrangement and construc-tion, many of the objects of the invention are attained in an acceptable fashion.
20 The size characteristics of the structure are well fixed and remain stable over a very long time. The wall thickness is close to that of natural human arteries ofsimilar duties and diameters, and the materials resist kinking when bent around short-radius curves at least as well as natural arteries do. The material is uniform throughout its length, so that a fabricated tube can be cut for use of any ~5 selected portion. The material sutures easily and with similar needle techniques to those used with natural arteries. The material does not rip nor tear any moreeasily than natural arteries do. Further7 the materials utilized provide a wall which is virtually impervious or leak-tight to blood. l issue does not lend to grow into or stiffen the material after installation.
30 It is therefore quite possible by utilizing the lay-up shown in FIGUR~ 3 and utilizing the materials specified in connection therewith and of the nature, size and characteristics stated to provide an excellent, long term readily handled and effective substitute for natural arteries.
~he arrangement of FIGURE 4 is very similar to that of FIGVRE 2. It differs in 7~5 _9_ that the microporous blood interface is eliminated. In the embodiment of FIGURE 4, the impervious inner zone 28 may be formed of polyether-polyurethane having an ultrasrnooth surface treted by gas plasma methods, for instance, to obtain an optimal hydrophobic surface. Wit'n such a construction, 5 the embodiment of FIGURE 4 is particularly suited to grafts of 5 mm internal diameter and smaller. Such smaller grafts may not be able to sustain a pseudointima without substantial risk of occlusion and the smooth hydrophobic surface will serve to prevent thrombus formation. Such antithromhogenic surfaces may remain "clean" except for a thin ~lycoprotein layer.
10 The embodiment of FIGURE 5, a preferred embodiment, is very similar to that of ~IGURE 1. The latter embodiment differs from the former in that a spiral reinforcement 29 is disposed in the interrnediate porous zone 7 rather than a net reinforcement about the outer porous zone 11. Moreover, in the embodiment of FIGURE 5, the impervious zone 9 is elirninated. While the embodiment of 15 ~IGURE 5 includes a microporous blood interface 109 it should be understood that a hydrophobic copolymer could be added, particularly on small grafts. The spiral reh~forcement 29 improves the anti-kinking characteristics of the graft;
achieves an adequate radial elastic modulus and at the same time a~oids any sharp or spiny protrusions when the graft is cut through. To this end it has been 20 found that the tensile elastic modulus of the spiral reinforcement filament itself should be in the range of from 109000 to 2,000,00Q psi. Moreover, the ratio of the dis~ance between spiral loops ~the pitch of the spiral) to the diameter of the filament itself should be in the range of from 1.5 to 5.
The embodiment of FIGURF ~ is particularly suited for small grafts. In this 25 instance the structure closely resembles that of FIGUE~E S but the blood interface 10 is elimin~ted. With such a structure the inner impervious zone 28, comparable to the zone 6 in FIGURE 5, may be .reated to make its surface hydrophobic and thus blood compatible. Grafts constructed ln accordance with this embodiment may have an internal diameter as soon as one millimeter.
30 There may be another alternate structure of the tubular substitute artery provided, as shown in FIGURE 7. In this instance the interior is symmetrical about an axis or center line 41 as before. The axis is generally symmetrically surrounded by a circular, thin solid elastomer zone 42 of segmented polyether-polyurethane. In this instance the zone 42 may be clear or lined -- if linedg then 35 having another solid elastomer zone 43 on the interior thereof. Surrounding the ~one 42 there is a relatively thick, generally porous, annular zone 44. This, in turn, is surrounded by an external zone 46 of a thin solid elastomeric material in turn encased in a porous elastomer zone 47. A unique feature in this instance isthat the major generally porous zone 44 is especially augmented by an enclosed, longitudinally extending, solid or high density porous elastomer 48 formed with 5 corrugations 49, the corrugations being either parallel and circular or contoured in a spiral path.
While it is usually customary to provide each of the vessels as a symmetrical construction of relatively unlimited length and extending along a central axis 51, the configuration need not include an entirely cylindrical enclosure as shown in10 FIGU~E 8. For example, and especially for use in relatively large diameter grafts; i.e. over eight millimeters inside diameter, there can be provided a zone setup very much as previously described but with the zones configured around the axis 51 in a convoluted structure 52. That is, the interior surface need notbe generally smooth, but may be undulatory or corrugated, with the different 15 undulations either having parallel circumferential paths or joined in a spiral path.
In this instance, as before, the inner blood contac~ing surface 53 may be a microporous blood interface. Next adjaceni is a solid ~lastomer zone 54, while surrounding that is a porous elastomer zone 56 of medium density. Around that next to the outside there is an impervious zone 579 and finally a porous elastomer 2Q tissue interface or zone 58 on top of everything. The embodiment of FIGURE 8,then, is similar to that of FIGURE 1 except that the reinforcement 12 of FIGUR~ 1 is replaced by the corrugated configuration of the overall prosthesis.
It should be recognized that the reinforcement of other embodiments described above, such for example, as that of FIGURE 5, may also be replaced by the 25 corrugated confi~uration as shown in FIGURE 8. Such configuration are particularly suitable ~or grafts havin~ an internal diameter oE from about 10 to30 millimeters.
In another variation, as particularly shown in FIGURE 9, there is a vessel symmetrical about a central axis 61. The inside zone 62 is formed of a porous 30 elastomer. Encasing this is a solid elastomer zone 63 which, in turn, is surrounded by a porous elastomer zone 64. The zone 64 is encased by a solid elastomer, undulatory zone 66 itself coated or surrounded by an external zone 67of a microporous tissue interface. Alternatively, the inner zone 62 may be eliminated and the smooth surfaced irnpervious zone 63 treated to be ~lood 35 compatible.
A somewhat different approach is shown in FIGURES 10 and 11. An encasing ~o~os wall shown generally at 81 is of a suitable material and multiple zones as previously described. Embedded in the wall and symmetrical about the central axis 82 is a helical reinforcement 83. This is preferably fabricated of a solid or quite dense porous elastomeric material. The reinforcement 83 in turn can also 5 be wrapped with a helical filament 84 comprised of plastic thread or metal wire.
As shown particularly in FIGURE 12, there is arranged around an axis 91, as before, first an inner surface ~one 92, followed by an impervious zone 93, a relatively porous, thick zone 94, a relatively solid outer zone 96 and finally an outside, thin, elastomeric zone ~7. Particularly, ~he zone 94 is especially 10 characteri~ed by a number of axially separated, embedded rings 98 to afford hoop strength and to maintain the axial disposition of the materials. The hoops 98 can be of a solid elastomer; of a hi~h density, porous elastomer; or of a rigid plastic such as a polyester. They even can be of metal such as stainless steel wire.
A variation on this theme is shown generally in FIGURE 13. The central axis 101 is as before and marks the center line of an inner microporous zone 105 withln asolid zone 106 in turn within a porous zone 107 surrounded by an outer solid zone 108 and an encompassing tissue interface 109. In this instance, there are inclined hoops 110. Instead of being circular in axial cross-section as the hoops 98 of FIGURE 12, the hoops 110 are rather of a radially elongated cross section approximately elliptical in pattern. The artery so furnished is relatively strong in a radial direction or a~ainst radial pressure.
In a similar arrangement in FIGURE 14, around the central axis 111 is substantially the same arrangement of zones 112, 113, 114, 116 and 117. In addition, there is an inner helical bo~y 118 of wire, plastic or elas~omer as well as a surrounding, outer helical body 119. 8ecause o~ the different diameters of the helical bodies, the pitches of their individual convolutions vary somewhat.
The general homogeneity of the blood vessel wall is not adversely affected by the periodical appearance of the reinforcements.
As a variation on this theme, there is provided, as shown in FIGURE 15, a comparable arrangement in which the various zones 121, 122, 124, 126 and 127 are symmetrical about a through axis 123. In this instance, the reinforcements are again in the generally porous central zone 124 and comprise wires 128 and 129, of either metal, elastomer or plastic disposed near the center and outside 35 respectively. These wires form nested3 circular rings. There is no axial ~2~7~
-12_ transmission of forces longitudinally along the length of the FlGURE 15 tube by the separate rings 128 and 129, as there may be along the convolutions 118 and 119 in the ~IGURE 14 version.
In the FIGURE 16 version, the zones 132, 123, 136, 137 and 138 are disposed about an axis 133. Symmetrical with the axis 133 are reinforcing rings 139. Thisarrangement is not especially restricted longitudinally, but is restricted circum-ferentially.
In the arrangement of FIGURE 17 the axis 141 is encompassed by the various zones 142, 143, 144, 14~ and 147. Within the zone 144 and around the axis 141 are spaced rings 148 of flat wire or plastic stock. Again, these are not constrictive in an axial direction, but, even more than the FIGURE 16 version, afford substantial radial restriction.
With all of these arrangements, it is found that the objects of the invention are in general met~ and that the natural arterial construction can be replaced by any of the constructions shown herein keeping in mind that the various forms of reinforcement may be utilized not only in the more complex joined zones of material, and any of the reinforcements described could be included in such a simple structure. Due regard may be had to the relative dimensions in diameter and length involved. Taken into appropriate account should be the juxtaposition 2a o~ the various materials and their own individual and relative dimensions. It has been found that substantially impervious, long-lived blood carrying vessels effective under normal human pressures and conditions are well provided in each instance.
30 Construction of an arterial graft prosthesis, as defined herein, results in static and dynamic moduli and pressure distortions in both radial and axial directions closely to match such distensions of normal human arteries of comparable diameter. Consequently, even after clamping, the prosthesis of the present invention, unlike the prior art prostheses, recover in the same manner as do 35 natural arteries. Also, $he wall thickness used is very close to that of human 1~7~05 arteries of a comparable diameter. ~urthermore, these prostheses, when formed, resist kinking when bent as well as the normal, natural arteries. There are uniform, homogeneous physical properties along the entire length of the insert or graft, so that the surgeon can cut an insert to any length he desires 5 with uniform results.
The prostheses defined suture as easily and with substantially the same needle penetration force and suture pull through force as l the case of natural arteries.
Also, sutures made in the prostheses do not pull out or tear to any greater extent or with any less force than those in a natural artery. The grafts defined, when 10 formed, are impervious or leak tight to the circulating blood. The customary needle holes are subs~antially immediately self-closing, so that they do not leak any contained blood. Furthermore, the prostheses inhibit tissue growth throug-hout the graft structure and so prevent a resultant sti~fening of the ~raft. They readily provide appropriate fixation for external tissue attachment and ready 15 avoidance of trapped fluids inside the tissue capsule. The prostheses are quite compatible with the customary blood and adjacent tissues. Also, the formed, indicated prostheses generally remain open and unobstructed indefinitely and without any adherent clot or the generation of internal thrombo-emboli. The net result is that the described prostheses afford an arterial replacement which is in 2~ most respects virtually indistinguishable from the original native artery.
In addition to the zones 6, 7 and 9, the embodiment of FIGURE 1 also includes a microporous blood interface 10. In an arterial graft of appro3~imately six millimeter internal diameter or more~ the blood ;nterface 10 may comprise a zone of "Biomer", having interior pores of a diameter and depth ranging from 25 five to one hundred microns, approximately. Preferably, the microporous tissue is trea.ted to be hydrophilic or hydrophobic, for instance, by subjection to known gas plasma or electrical discharge methods. The so-trea~ed microporous tissue interface is effective as an anchoring substrate for a developing pseudointirna which form~ blood constituents. This pseudointima is a ~issue layer which must 30 adhere to the blood interface and remains quite thin. If desired, the hydrophilic or hydrophobic microporous blood interface may be coated with an antithrombin such as albumin, gelatin, glycoproteins, bonded heparin or comparable material to prevent or to diminish any early thrombus formation. Such initial coatings, in use, may gradually be replaced with the developing pseudointima as described.
35 About the outside of the graft is an adheran~ surrounding tissue interface 11.
The material of the interface 11, like the blood interface 10, may also be a ~2~710S
microporous "Biomer" but ~ith slightly larger pores -- in the range of thirty toone hundred fifty microns. The surface of this interface may also and similarly be made hydrophilic or hydrophobic.
Particularly for the porous core 7 but also for the interfaces 10 and 11, the 5 homogeneous pores are initially formed by the use of partlculates such as salt(NaCI) or sodium bicarbonate, which is ultimately largely removed by diffusion in a water or very dilute acid bath. The sodium bicarbonate also acts as a blowing agent in that the CO2 is released and thus decreases the amount of salt to be removed from the core. The particulates utilized for this purpose are screened lû to afford a very narrow range of sizes, so that the pore sizes themselves areconfined to a very narrow range. The result is a porous of foam-like structure containing closed-cell or open-cell voids with a substantially reduced general density.
The salt particles, for example, and the "aiomer" or core solution are completely 15 and homo~eneously mixed to form a slurry. Different slurries, with or withoutsalt particles, are then used to form the various zones on a mandrel. The first slurry (with salt or sodium bicarbonate particle size to produce pores of frorn five to one hundred microns) is applied directly to the mandrel by dipping, coating or doctoring to form the zone 10. This is followed by an unsalted 20 solution to form the zone 6 and the sequence is continual until the entire graft is fabricated. The coatings on the mandrel are then thoroughly dried to remove the solvent and then the salt or bicarbonate particles are removed in a water bath at about 60 C. There are water-filled voids so created by the dissolution and diffusion OI the salt particles. The particle size and concentratlon of particles 25 are arranged to control the density or porosity and pore size. For example, sodium chloride part;cles of ~bout ~ifty micron average size are used for the zone 7 and the optimum range is within about one to one hundred fifty microns.
The total void volume is about fifty per cent of the total layer volume, the range being from about thirty percent to ninety percen~.
30 The result of the foregoing is the production of a readily patent and clinically superior tubular graft which simulates very closely the properties of a natural artery. This provides that the artificial graft can be sutured to adjacent arteries very much as though a natural artery were utilized. The dimensional and distensional simulat;on by the artificial material to the natural material reduces ~5 or eliminates sutureline disc~ntinuities and obstructions. Furthermore, grafts of ~;~871~)5 the present prostheses behave very much like the natural artery, so that the surgeon's sl;ill and experience are fully utilized. Also, the grafts of .n~ presen.
prostheses provide the same suturability, feedom from kinking, clamping charac-teristics, impermeability, biocompatability, antithrombogenicity, patency, and 5 other advantages of natural arterial material.
Although the present artificial construction has two or often three zones, nevertheless the several zones allow Eor the provision of individual or separatecomponent characteristics, preferably all based on the polyether-polyurethane structure.
10 In some instances, it is desirable to surround the exterior o the artificial artery so provided with a confining netting 12 of "Dacron" or the like or a circumferen-tial winding of 2 suitable filament 13 ~see FIGURE 2) which may be formed of "Dacron", solid elastomer, wire or the like. When external, as in FIGURE 11 thisreinforcement is customarily adhesively affixed at spaced intervals and loosely 1~ surrounds the remainder o~ the artificial artery. The netting comes into playprimarily only in the event there is a substantial expansion of the artery. The netting confines the amount of such expansion to preclude undue stretching and thinning of the artery walls.
As an alternative to the attachment of the reinforcing material to the outer 20 zone of the prosthesis, as shown in FIGURE 1, it rnay be formed within one ormore of the zones of elastomer as particularly shown in FlGURE 2, the purpose here also being to preclude undue expansion of the artificial arter~.
Clinical experience has indicated that an artificial artery constructed as described herein and particularly fabricated primarily of polyether-polyurethane25 is virtually indistinguishable from the naturally occurring artery which it replaces and afford a long term, effective and trouble free substitute for the originally occurring, natural artery.
The alternative embodiment of FIGURE 2 differs from that of FiGURE 1 not only in the type of reinfoFcing material, but also in that the tissue interface 11 is 30 eliminated.
Another modified graft as shown in FIGURE 3 is a section 21 acting as an artery generally symmetrical about a longitudinal axis 22 and particularly inclusive ofan inside zone 23 of relatively solid polyether-polyurethane, preferably of * Trade Mark ~2~'7~0S
segmented polyether-polyurethane. The zone 23 is arranged symmetrically about the axis 22 or approximately SQ and on its inner surface is covered particularlywith an inner coat 24 of a micro porous blood interface of polyether-polyurethane. The pores in the interface coat 24 are in the range of five to one5 hundred microns in size and depth, and the coat itself is treated primarily to be hydrophilic.
The inside zone 23 and the inside coat 24 line a tubular zone or body 26 of a porous, segmented polyether-polyurethane having pores of about one to one hundred fifty microns in size. The pores are sufficient in number and disposition 10 to allow from a~out thirty per cent to ninety per cent of the zone 26 to consist of pores.
Around the tubular body 26 there is a further zone ~7 of relatively solid polyether-polyurethane about one to six mils thick. Finally~ surrounding the zone 27 there is a generally exposed microporous tissue interface 2~ comprised 15 of polyether-polyurethane having pores of about thirty to one hundred fifty microns in size and depth. This e3~terior interface 28 likewise is treated to behydrophilic.
It is found that with these materials and this general arrangement and construc-tion, many of the objects of the invention are attained in an acceptable fashion.
20 The size characteristics of the structure are well fixed and remain stable over a very long time. The wall thickness is close to that of natural human arteries ofsimilar duties and diameters, and the materials resist kinking when bent around short-radius curves at least as well as natural arteries do. The material is uniform throughout its length, so that a fabricated tube can be cut for use of any ~5 selected portion. The material sutures easily and with similar needle techniques to those used with natural arteries. The material does not rip nor tear any moreeasily than natural arteries do. Further7 the materials utilized provide a wall which is virtually impervious or leak-tight to blood. l issue does not lend to grow into or stiffen the material after installation.
30 It is therefore quite possible by utilizing the lay-up shown in FIGUR~ 3 and utilizing the materials specified in connection therewith and of the nature, size and characteristics stated to provide an excellent, long term readily handled and effective substitute for natural arteries.
~he arrangement of FIGURE 4 is very similar to that of FIGVRE 2. It differs in 7~5 _9_ that the microporous blood interface is eliminated. In the embodiment of FIGURE 4, the impervious inner zone 28 may be formed of polyether-polyurethane having an ultrasrnooth surface treted by gas plasma methods, for instance, to obtain an optimal hydrophobic surface. Wit'n such a construction, 5 the embodiment of FIGURE 4 is particularly suited to grafts of 5 mm internal diameter and smaller. Such smaller grafts may not be able to sustain a pseudointima without substantial risk of occlusion and the smooth hydrophobic surface will serve to prevent thrombus formation. Such antithromhogenic surfaces may remain "clean" except for a thin ~lycoprotein layer.
10 The embodiment of FIGURE 5, a preferred embodiment, is very similar to that of ~IGURE 1. The latter embodiment differs from the former in that a spiral reinforcement 29 is disposed in the interrnediate porous zone 7 rather than a net reinforcement about the outer porous zone 11. Moreover, in the embodiment of FIGURE 5, the impervious zone 9 is elirninated. While the embodiment of 15 ~IGURE 5 includes a microporous blood interface 109 it should be understood that a hydrophobic copolymer could be added, particularly on small grafts. The spiral reh~forcement 29 improves the anti-kinking characteristics of the graft;
achieves an adequate radial elastic modulus and at the same time a~oids any sharp or spiny protrusions when the graft is cut through. To this end it has been 20 found that the tensile elastic modulus of the spiral reinforcement filament itself should be in the range of from 109000 to 2,000,00Q psi. Moreover, the ratio of the dis~ance between spiral loops ~the pitch of the spiral) to the diameter of the filament itself should be in the range of from 1.5 to 5.
The embodiment of FIGURF ~ is particularly suited for small grafts. In this 25 instance the structure closely resembles that of FIGUE~E S but the blood interface 10 is elimin~ted. With such a structure the inner impervious zone 28, comparable to the zone 6 in FIGURE 5, may be .reated to make its surface hydrophobic and thus blood compatible. Grafts constructed ln accordance with this embodiment may have an internal diameter as soon as one millimeter.
30 There may be another alternate structure of the tubular substitute artery provided, as shown in FIGURE 7. In this instance the interior is symmetrical about an axis or center line 41 as before. The axis is generally symmetrically surrounded by a circular, thin solid elastomer zone 42 of segmented polyether-polyurethane. In this instance the zone 42 may be clear or lined -- if linedg then 35 having another solid elastomer zone 43 on the interior thereof. Surrounding the ~one 42 there is a relatively thick, generally porous, annular zone 44. This, in turn, is surrounded by an external zone 46 of a thin solid elastomeric material in turn encased in a porous elastomer zone 47. A unique feature in this instance isthat the major generally porous zone 44 is especially augmented by an enclosed, longitudinally extending, solid or high density porous elastomer 48 formed with 5 corrugations 49, the corrugations being either parallel and circular or contoured in a spiral path.
While it is usually customary to provide each of the vessels as a symmetrical construction of relatively unlimited length and extending along a central axis 51, the configuration need not include an entirely cylindrical enclosure as shown in10 FIGU~E 8. For example, and especially for use in relatively large diameter grafts; i.e. over eight millimeters inside diameter, there can be provided a zone setup very much as previously described but with the zones configured around the axis 51 in a convoluted structure 52. That is, the interior surface need notbe generally smooth, but may be undulatory or corrugated, with the different 15 undulations either having parallel circumferential paths or joined in a spiral path.
In this instance, as before, the inner blood contac~ing surface 53 may be a microporous blood interface. Next adjaceni is a solid ~lastomer zone 54, while surrounding that is a porous elastomer zone 56 of medium density. Around that next to the outside there is an impervious zone 579 and finally a porous elastomer 2Q tissue interface or zone 58 on top of everything. The embodiment of FIGURE 8,then, is similar to that of FIGURE 1 except that the reinforcement 12 of FIGUR~ 1 is replaced by the corrugated configuration of the overall prosthesis.
It should be recognized that the reinforcement of other embodiments described above, such for example, as that of FIGURE 5, may also be replaced by the 25 corrugated confi~uration as shown in FIGURE 8. Such configuration are particularly suitable ~or grafts havin~ an internal diameter oE from about 10 to30 millimeters.
In another variation, as particularly shown in FIGURE 9, there is a vessel symmetrical about a central axis 61. The inside zone 62 is formed of a porous 30 elastomer. Encasing this is a solid elastomer zone 63 which, in turn, is surrounded by a porous elastomer zone 64. The zone 64 is encased by a solid elastomer, undulatory zone 66 itself coated or surrounded by an external zone 67of a microporous tissue interface. Alternatively, the inner zone 62 may be eliminated and the smooth surfaced irnpervious zone 63 treated to be ~lood 35 compatible.
A somewhat different approach is shown in FIGURES 10 and 11. An encasing ~o~os wall shown generally at 81 is of a suitable material and multiple zones as previously described. Embedded in the wall and symmetrical about the central axis 82 is a helical reinforcement 83. This is preferably fabricated of a solid or quite dense porous elastomeric material. The reinforcement 83 in turn can also 5 be wrapped with a helical filament 84 comprised of plastic thread or metal wire.
As shown particularly in FIGURE 12, there is arranged around an axis 91, as before, first an inner surface ~one 92, followed by an impervious zone 93, a relatively porous, thick zone 94, a relatively solid outer zone 96 and finally an outside, thin, elastomeric zone ~7. Particularly, ~he zone 94 is especially 10 characteri~ed by a number of axially separated, embedded rings 98 to afford hoop strength and to maintain the axial disposition of the materials. The hoops 98 can be of a solid elastomer; of a hi~h density, porous elastomer; or of a rigid plastic such as a polyester. They even can be of metal such as stainless steel wire.
A variation on this theme is shown generally in FIGURE 13. The central axis 101 is as before and marks the center line of an inner microporous zone 105 withln asolid zone 106 in turn within a porous zone 107 surrounded by an outer solid zone 108 and an encompassing tissue interface 109. In this instance, there are inclined hoops 110. Instead of being circular in axial cross-section as the hoops 98 of FIGURE 12, the hoops 110 are rather of a radially elongated cross section approximately elliptical in pattern. The artery so furnished is relatively strong in a radial direction or a~ainst radial pressure.
In a similar arrangement in FIGURE 14, around the central axis 111 is substantially the same arrangement of zones 112, 113, 114, 116 and 117. In addition, there is an inner helical bo~y 118 of wire, plastic or elas~omer as well as a surrounding, outer helical body 119. 8ecause o~ the different diameters of the helical bodies, the pitches of their individual convolutions vary somewhat.
The general homogeneity of the blood vessel wall is not adversely affected by the periodical appearance of the reinforcements.
As a variation on this theme, there is provided, as shown in FIGURE 15, a comparable arrangement in which the various zones 121, 122, 124, 126 and 127 are symmetrical about a through axis 123. In this instance, the reinforcements are again in the generally porous central zone 124 and comprise wires 128 and 129, of either metal, elastomer or plastic disposed near the center and outside 35 respectively. These wires form nested3 circular rings. There is no axial ~2~7~
-12_ transmission of forces longitudinally along the length of the FlGURE 15 tube by the separate rings 128 and 129, as there may be along the convolutions 118 and 119 in the ~IGURE 14 version.
In the FIGURE 16 version, the zones 132, 123, 136, 137 and 138 are disposed about an axis 133. Symmetrical with the axis 133 are reinforcing rings 139. Thisarrangement is not especially restricted longitudinally, but is restricted circum-ferentially.
In the arrangement of FIGURE 17 the axis 141 is encompassed by the various zones 142, 143, 144, 14~ and 147. Within the zone 144 and around the axis 141 are spaced rings 148 of flat wire or plastic stock. Again, these are not constrictive in an axial direction, but, even more than the FIGURE 16 version, afford substantial radial restriction.
With all of these arrangements, it is found that the objects of the invention are in general met~ and that the natural arterial construction can be replaced by any of the constructions shown herein keeping in mind that the various forms of reinforcement may be utilized not only in the more complex joined zones of material, and any of the reinforcements described could be included in such a simple structure. Due regard may be had to the relative dimensions in diameter and length involved. Taken into appropriate account should be the juxtaposition 2a o~ the various materials and their own individual and relative dimensions. It has been found that substantially impervious, long-lived blood carrying vessels effective under normal human pressures and conditions are well provided in each instance.
Claims (36)
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. An arterial graft prosthesis formed of a core zone of porous elastomer disposed about the longitudinal axis of the prosthesis, an inner zone of solid elastomer concentric with and homogeneously joined to the inside of said zone of porous elastomer, said inner zone forming the inner surface of said prosthesis.
2. An arterial graft prosthesis formed of a core zone of porous elastomer disposed about the longitudinal axis of the prosthesis, an inner zone of said elastomer concentric with and homogeneously joined to the inside of said zone of porous elastomer, an outer zone of solid elastomer, said outer zone of solid elastomer being concentric with and homogeneously joined to the outside of said zone of porous elastomer.
3. An arterial graft prosthesis as defined in claim 2, together with a tissue interface zone of microporous elastomer concentric with and homogeneously joined to the outside of said outer zone of solid elastomer.
4. An arterial graft prosthesis as defined in claim 1, 2 or 3, wherein said solid elastomer is hydrophobic.
5. An arterial graft prosthesis formed of a core zone of porous elastomer disposed about the longitudinal axis of the prosthesis, an outer zone of solid elastomer, said outer zone of solid elastomer being concentric with and homogeneously joined to the outside of said zone of porous elastomer, said outer zone forming the outer surface of said prosthesis.
6. An arterial graft prosthesis as defined in claim 2, 3 or 5, together with a blood interface zone of microporous elastomer concentric with and homogeneously joined to the inside of said inner zone of solid elastomer.
7. An arterial graft prosthesis as defined in claim 1, wherein said core zone has a thickness of from 10 to 80 mils.
8. An arterial graft prosthesis as defined in claim 5, wherein said core zone has a thickness of from 10 to 80 mils.
9. An arterial graft prostheses as defined in claim 7 or 8, wherein said core zone defines pores comprising from 30% to 90% of its volume, said pores having a diameter and depth of up to 150 microns.
10. An arterial graft prosthesis as defined in claim 1, 2 or 3, wherein said inner zone of solid elastomer has a thickness of from 1 to 6 mils.
11. An arterial graft prosthesis as defined in claim 2, 3 or 5, wherein said outer zone of solid elastomer has a thickness of from 1 to 6 mils.
12. An arterial graft prosthesis as defined in claim 3, wherein said tissue interface zone defines pores having a diameter and depth of from 30 to 150 microns.
13. An arterial graft prosthesis as defined in claim 1, 2 or 3, together with a blood interface zone of microporous elastomer concentric with and homogeneously joined to the inside of said inner zone of solid elastomer said blood interface zone defining pores having a diameter and depth of from 5 to 100 microns.
14. An arterial graft prosthesis as defined in claim 1, 2 or 3, wherein said elastomer material is a thermoplastic.
15. An arterial graft prosthesis as defined in claim 1, 2 or 3, wherein said elastomer material is a segmented polyether-polyurethane.
16. An arterial graft prosthesis as defined in claim 3, wherein the surface of said tissue interface zone is hydrophilic.
17. An arterial graft prosthesis as defined in claim 1, 2 or 3, together with a blood interface zone of microporous elastomer concentric with and homogeneously joined to the inside of said inner zone of solid elastomer wherein a surface of said blood interface zone is hydrophilic.
18. An arterial graft prosthesis as defined in claim 1, 2 or 3, together with a blood interface zone of microporous elastomer concentric with and homogeneously joined to the inside of said inner zone of solid elastomer wherein a surface of said blood interface zone is hydrophilic and is coated with an anti-thrombin.
19. An arterial graft prosthesis as defined in claim 1, together with reinforcing means connected to one of said zones of elastomer.
20. An arterial graft prosthesis as defined in claim 19, wherein said reinforcing means is disposed about the outer zone of said prosthesis.
21. An arterial graft prosthesis as defined in claim 19, wherein said reinforcing means is disposed within at least one of said zones of elastomer.
22. An arterial graft prosthesis as defined in claim 19, wherein said reinforcing means comprises a non-stretchable netting.
23. An arterial graft prosthesis as defined in claim 19, wherein said reinforcing means comprises a filament circumfer-entially wound about the longitudinal axis of said prosthesis.
24. An arterial graft prosthesis as defined in claim 23, wherein said filament has a tensile elastic modulus in the range of from 10,000 to 200,000 psi.
25. An arterial graft prosthesis as defined in claim 24, wherein the ratio of the distance between loops of the circumfer-entially wound filament to the diameter of said filament lies in the range of from 1.5 to 5.
26. An arterial graft prosthesis as defined in claim 21, wherein said reinforcing means comprises an elastomer formed as a corrugated tube.
27. An arterial graft prosthesis as defined in claim 21, wherein said reinforcing means comprises a helically wound filament.
28. An arterial graft prosthesis as defined in claim 21, wherein said reinforcing means comprises a plurality of axially spaced hoops.
29. An arterial graft prosthesis as defined in claim 1, wherein the outer surface of said core zone and of said prosthesis is corrugated.
30. An arterial graft prosthesis as defined in claim 5, wherein the outer surface of said core zone and of said prosthesis is corrugated.
31. An arterial graft prosthesis as defined in claim 29 or 30, wherein the inner surfaces of said core zone and of said prosthesis is corrugated.
32. An arterial graft prosthesis formed of at least two concentric tubular zones of elastomer material homogeneously joined together, one of said zones being a porous elastomer, and reinforcing means disposed in at least one of said zones of elastomer, said reinforcing means comprising an elastomer formed as a corrugated tube.
33. An arterial graft prosthesis formed of at least two concentric tubular zones of elastomer material homogeneously joined together, one of said zones being a porous elastomer, and reinforcing means disposed within at least one of said zones of elastomer, said reinforcing means comprising a plurality of axially spaced hoops.
34. An arterial graft prosthesis formed of at least two concentric tubular zones of elastomer material homogeneously joined together, one of said zones being a porous elastomer, the outer surface of the outermost of said zones being corrugated.
35. An arterial graft prosthesis as defined in claim 34, wherein the inner surface of the innermost of said zones is corrugated.
36. An arterial graft prosthesis formed of a core zone of porous elastomer disposed about the longitudinal axis of the prosthesis, an inner zone of solid elastomer concentric with and homogeneously joined to the inside of said core zone, an outer zone of porous elastomer, said outer zone of porous elastomer being concentric with and homogeneously joined to the outside of said core zone.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/234,116 US4604762A (en) | 1981-02-13 | 1981-02-13 | Arterial graft prosthesis |
US234,116 | 1994-04-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1207105A true CA1207105A (en) | 1986-07-08 |
Family
ID=22879993
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000396176A Expired CA1207105A (en) | 1981-02-13 | 1982-02-12 | Arterial graft prosthesis |
Country Status (6)
Country | Link |
---|---|
US (2) | US4604762A (en) |
JP (1) | JPS57150954A (en) |
CA (1) | CA1207105A (en) |
DE (1) | DE3204719A1 (en) |
FR (1) | FR2499847B1 (en) |
GB (1) | GB2092894B (en) |
Families Citing this family (236)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE446372B (en) * | 1983-02-03 | 1986-09-08 | Medinvent Sa | BLOODKERL PROTES FOR USE AS SHUNT BETWEEN BLOODKERL |
EP0128501B1 (en) * | 1983-06-06 | 1989-03-29 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Artificial vessel and process for preparing the same |
JPS60188164A (en) * | 1984-03-07 | 1985-09-25 | 鐘淵化学工業株式会社 | Artifical vessel |
EP0130401B1 (en) * | 1983-06-06 | 1989-05-17 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Artificial vessel and process for preparing the same |
JPS60182958A (en) * | 1984-03-01 | 1985-09-18 | 鐘淵化学工業株式会社 | Artifical vessel |
JPS602254A (en) * | 1983-06-18 | 1985-01-08 | 鐘淵化学工業株式会社 | Artificial blood vessel and production thereof |
JPS602257A (en) * | 1983-06-20 | 1985-01-08 | 鐘淵化学工業株式会社 | New artificial blood vessel |
DE3329733A1 (en) * | 1983-08-17 | 1985-03-07 | Johannes Dr.med. 6500 Mainz Reinmüller | PLASTIC IMPLANT |
JPS6099258A (en) * | 1983-11-02 | 1985-06-03 | 東レ株式会社 | Artificial blood vessel |
JPS61185271A (en) * | 1985-02-09 | 1986-08-18 | 鐘淵化学工業株式会社 | Artificial blood vessel of which compliance and stress-strain curve are similar to live blood vessel and itsproduction |
JPS60194956A (en) * | 1984-03-16 | 1985-10-03 | 鐘淵化学工業株式会社 | Production of artificial vessel |
DE3566498D1 (en) * | 1984-03-01 | 1989-01-05 | Kanegafuchi Chemical Ind | Artificial vessel and process for preparing the same |
JPS60242857A (en) * | 1984-05-17 | 1985-12-02 | 工業技術院長 | Artificial blood vessel |
JPS6173650A (en) * | 1984-09-19 | 1986-04-15 | 宇部興産株式会社 | Polyurethane blood vessel prosthesis and its production |
JPS6187563A (en) * | 1984-10-05 | 1986-05-02 | 宇部興産株式会社 | Medical molded article |
JPS61238238A (en) * | 1985-04-15 | 1986-10-23 | 鐘淵化学工業株式会社 | Production of artificial blood vessel |
JPS6264361A (en) * | 1985-09-12 | 1987-03-23 | 鐘淵化学工業株式会社 | Artificial blood vessel |
EP0217115B1 (en) * | 1985-08-26 | 1989-10-25 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Artificial vessel |
GB2195251A (en) * | 1986-09-02 | 1988-04-07 | Ethicon Inc | Improvements in synthetic vascular grafts |
JPS6395050A (en) * | 1986-10-08 | 1988-04-26 | 鐘淵化学工業株式会社 | Artificial blood vessel |
JPH0696023B2 (en) * | 1986-11-10 | 1994-11-30 | 宇部日東化成株式会社 | Artificial blood vessel and method for producing the same |
JPS63209647A (en) * | 1987-02-26 | 1988-08-31 | 鐘淵化学工業株式会社 | Artificial blood vessel |
JPS63270048A (en) * | 1987-04-30 | 1988-11-08 | Ube Ind Ltd | Artificial blood vessel |
JPS63305860A (en) * | 1987-06-05 | 1988-12-13 | Ube Ind Ltd | Artificial blood vessel |
US4986832A (en) * | 1987-09-04 | 1991-01-22 | Ube Industries, Ltd. | Artificial blood vessel and process for preparing it |
US5133732A (en) * | 1987-10-19 | 1992-07-28 | Medtronic, Inc. | Intravascular stent |
US4906423A (en) * | 1987-10-23 | 1990-03-06 | Dow Corning Wright | Methods for forming porous-surfaced polymeric bodies |
US4892544A (en) * | 1988-03-07 | 1990-01-09 | Dow Corning Wright Corporation | Methods for forming hollow, porous-surfaced elastomeric bodies |
JPH01250249A (en) * | 1988-03-31 | 1989-10-05 | Kanegafuchi Chem Ind Co Ltd | Artificial blood vessel for accessing blood |
DE3830481A1 (en) * | 1988-09-08 | 1990-03-22 | Ethicon Gmbh | Tubular implant and method of producing it |
CA2004833A1 (en) * | 1988-12-08 | 1990-06-08 | Leonard Armand Trudell | Prosthesis of foam polyurethane and collagen and uses thereof |
US5207705A (en) * | 1988-12-08 | 1993-05-04 | Brigham And Women's Hospital | Prosthesis of foam polyurethane and collagen and uses thereof |
US4969896A (en) * | 1989-02-01 | 1990-11-13 | Interpore International | Vascular graft prosthesis and method of making the same |
JPH02255139A (en) * | 1989-02-28 | 1990-10-15 | David C Macgregor | Device for orthopedic operation |
US5674278A (en) * | 1989-08-24 | 1997-10-07 | Arterial Vascular Engineering, Inc. | Endovascular support device |
US6344053B1 (en) | 1993-12-22 | 2002-02-05 | Medtronic Ave, Inc. | Endovascular support device and method |
DE3930770A1 (en) * | 1989-09-14 | 1991-03-28 | Wolfgang F Dr Schoener | IMPLANTABLE CATHETERS MADE FROM MEDICAL COMPATIBLE ELASTIC PLASTIC |
GB8923516D0 (en) * | 1989-10-18 | 1989-12-06 | Newtec V P Ltd | Polymer products |
US5549860A (en) * | 1989-10-18 | 1996-08-27 | Polymedica Industries, Inc. | Method of forming a vascular prosthesis |
US5123917A (en) * | 1990-04-27 | 1992-06-23 | Lee Peter Y | Expandable intraluminal vascular graft |
US5236447A (en) * | 1990-06-29 | 1993-08-17 | Nissho Corporation | Artificial tubular organ |
EP0495127B1 (en) * | 1990-07-31 | 1996-11-27 | Ube Industries, Ltd. | Artificial blood vessel and production thereof |
US5549664A (en) * | 1990-07-31 | 1996-08-27 | Ube Industries, Ltd. | Artificial blood vessel |
GB9025382D0 (en) * | 1990-11-22 | 1991-01-09 | Newtec V P Ltd | Polymer products |
US5632776A (en) * | 1990-11-22 | 1997-05-27 | Toray Industries, Inc. | Implantation materials |
US5320100A (en) * | 1991-09-16 | 1994-06-14 | Atrium Medical Corporation | Implantable prosthetic device having integral patency diagnostic indicia |
WO1993006792A1 (en) * | 1991-10-04 | 1993-04-15 | Scimed Life Systems, Inc. | Biodegradable drug delivery vascular stent |
US5662713A (en) * | 1991-10-09 | 1997-09-02 | Boston Scientific Corporation | Medical stents for body lumens exhibiting peristaltic motion |
US5866217A (en) * | 1991-11-04 | 1999-02-02 | Possis Medical, Inc. | Silicone composite vascular graft |
FR2688401B1 (en) * | 1992-03-12 | 1998-02-27 | Thierry Richard | EXPANDABLE STENT FOR HUMAN OR ANIMAL TUBULAR MEMBER, AND IMPLEMENTATION TOOL. |
US5246452A (en) * | 1992-04-13 | 1993-09-21 | Impra, Inc. | Vascular graft with removable sheath |
DE4222380A1 (en) * | 1992-07-08 | 1994-01-13 | Ernst Peter Prof Dr M Strecker | Endoprosthesis implantable percutaneously in a patient's body |
US5716395A (en) * | 1992-12-11 | 1998-02-10 | W.L. Gore & Associates, Inc. | Prosthetic vascular graft |
US5628782A (en) * | 1992-12-11 | 1997-05-13 | W. L. Gore & Associates, Inc. | Method of making a prosthetic vascular graft |
BE1006440A3 (en) * | 1992-12-21 | 1994-08-30 | Dereume Jean Pierre Georges Em | Luminal endoprosthesis AND METHOD OF PREPARATION. |
US5334201A (en) * | 1993-03-12 | 1994-08-02 | Cowan Kevin P | Permanent stent made of a cross linkable material |
US6685736B1 (en) * | 1993-09-30 | 2004-02-03 | Endogad Research Pty Limited | Intraluminal graft |
US5723004A (en) | 1993-10-21 | 1998-03-03 | Corvita Corporation | Expandable supportive endoluminal grafts |
US5632772A (en) * | 1993-10-21 | 1997-05-27 | Corvita Corporation | Expandable supportive branched endoluminal grafts |
US5855598A (en) * | 1993-10-21 | 1999-01-05 | Corvita Corporation | Expandable supportive branched endoluminal grafts |
US5639278A (en) * | 1993-10-21 | 1997-06-17 | Corvita Corporation | Expandable supportive bifurcated endoluminal grafts |
US5527353A (en) | 1993-12-02 | 1996-06-18 | Meadox Medicals, Inc. | Implantable tubular prosthesis |
US6039749A (en) | 1994-02-10 | 2000-03-21 | Endovascular Systems, Inc. | Method and apparatus for deploying non-circular stents and graftstent complexes |
US5549663A (en) * | 1994-03-09 | 1996-08-27 | Cordis Corporation | Endoprosthesis having graft member and exposed welded end junctions, method and procedure |
US6165210A (en) * | 1994-04-01 | 2000-12-26 | Gore Enterprise Holdings, Inc. | Self-expandable helical intravascular stent and stent-graft |
US6001123A (en) * | 1994-04-01 | 1999-12-14 | Gore Enterprise Holdings Inc. | Folding self-expandable intravascular stent-graft |
DE4414103A1 (en) * | 1994-04-22 | 1995-10-26 | Reinmueller Johannes | Molded medical implants |
US8697108B2 (en) * | 1994-05-13 | 2014-04-15 | Kensey Nash Corporation | Method for making a porous polymeric material |
DE69518435T3 (en) * | 1994-06-08 | 2004-07-22 | CardioVascular Concepts, Inc., Portola Valley | A branching graft manufacturing system |
US6331188B1 (en) | 1994-08-31 | 2001-12-18 | Gore Enterprise Holdings, Inc. | Exterior supported self-expanding stent-graft |
US6015429A (en) | 1994-09-08 | 2000-01-18 | Gore Enterprise Holdings, Inc. | Procedures for introducing stents and stent-grafts |
DE4446036C2 (en) * | 1994-12-23 | 1999-06-02 | Ruesch Willy Ag | Placeholder for placement in a body tube |
US6264684B1 (en) * | 1995-03-10 | 2001-07-24 | Impra, Inc., A Subsidiary Of C.R. Bard, Inc. | Helically supported graft |
US6053943A (en) * | 1995-12-08 | 2000-04-25 | Impra, Inc. | Endoluminal graft with integral structural support and method for making same |
US6039755A (en) * | 1997-02-05 | 2000-03-21 | Impra, Inc., A Division Of C.R. Bard, Inc. | Radially expandable tubular polytetrafluoroethylene grafts and method of making same |
US6451047B2 (en) | 1995-03-10 | 2002-09-17 | Impra, Inc. | Encapsulated intraluminal stent-graft and methods of making same |
WO1996028115A1 (en) * | 1995-03-10 | 1996-09-19 | Impra, Inc. | Endoluminal encapsulated stent and methods of manufacture and endoluminal delivery |
US6124523A (en) * | 1995-03-10 | 2000-09-26 | Impra, Inc. | Encapsulated stent |
BE1009278A3 (en) * | 1995-04-12 | 1997-01-07 | Corvita Europ | Guardian self-expandable medical device introduced in cavite body, and medical device with a stake as. |
BE1009277A3 (en) | 1995-04-12 | 1997-01-07 | Corvita Europ | Guardian self-expandable medical device introduced in cavite body, and method of preparation. |
US5613981A (en) * | 1995-04-21 | 1997-03-25 | Medtronic, Inc. | Bidirectional dual sinusoidal helix stent |
US5667523A (en) * | 1995-04-28 | 1997-09-16 | Impra, Inc. | Dual supported intraluminal graft |
US5700269A (en) * | 1995-06-06 | 1997-12-23 | Corvita Corporation | Endoluminal prosthesis deployment device for use with prostheses of variable length and having retraction ability |
US6010530A (en) * | 1995-06-07 | 2000-01-04 | Boston Scientific Technology, Inc. | Self-expanding endoluminal prosthesis |
US5676685A (en) * | 1995-06-22 | 1997-10-14 | Razavi; Ali | Temporary stent |
DE69533289T2 (en) | 1995-08-24 | 2005-08-18 | Bard Peripheral Vascular, Inc., Tempe | ARRANGEMENT PROCESS OF A COVERED, ENDOLUMINARY STENT |
US5562697A (en) * | 1995-09-18 | 1996-10-08 | William Cook, Europe A/S | Self-expanding stent assembly and methods for the manufacture thereof |
DE19539449A1 (en) * | 1995-10-24 | 1997-04-30 | Biotronik Mess & Therapieg | Process for the production of intraluminal stents from bioresorbable polymer material |
US6348066B1 (en) * | 1995-11-07 | 2002-02-19 | Corvita Corporation | Modular endoluminal stent-grafts and methods for their use |
US5628788A (en) * | 1995-11-07 | 1997-05-13 | Corvita Corporation | Self-expanding endoluminal stent-graft |
US6929659B2 (en) | 1995-11-07 | 2005-08-16 | Scimed Life Systems, Inc. | Method of preventing the dislodgment of a stent-graft |
US6562781B1 (en) | 1995-11-30 | 2003-05-13 | Hamilton Civic Hospitals Research Development Inc. | Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates |
US6491965B1 (en) * | 1995-11-30 | 2002-12-10 | Hamilton Civic Hospitals Research Development, Inc. | Medical device comprising glycosaminoglycan-antithrombin III/heparin cofactor II conjugates |
US7045585B2 (en) * | 1995-11-30 | 2006-05-16 | Hamilton Civic Hospital Research Development Inc. | Methods of coating a device using anti-thrombin heparin |
US6042605A (en) | 1995-12-14 | 2000-03-28 | Gore Enterprose Holdings, Inc. | Kink resistant stent-graft |
EP0950385A3 (en) | 1995-12-14 | 1999-10-27 | Prograft Medical, Inc. | Stent-graft deployment apparatus and method |
US5865723A (en) * | 1995-12-29 | 1999-02-02 | Ramus Medical Technologies | Method and apparatus for forming vascular prostheses |
US5843158A (en) * | 1996-01-05 | 1998-12-01 | Medtronic, Inc. | Limited expansion endoluminal prostheses and methods for their use |
EP0955954B1 (en) | 1996-01-05 | 2005-03-16 | Medtronic, Inc. | Expansible endoluminal prostheses |
CA2199890C (en) * | 1996-03-26 | 2002-02-05 | Leonard Pinchuk | Stents and stent-grafts having enhanced hoop strength and methods of making the same |
FR2747301B1 (en) * | 1996-04-10 | 1998-09-18 | Nycomed Lab Sa | IMPLANTABLE DEVICE FOR MAINTAINING OR RE-ESTABLISHING THE NORMAL PASSAGE SECTION OF A BODY DUCT, AS WELL AS A SYSTEM FOR ITS PLACEMENT |
US5951586A (en) * | 1996-05-15 | 1999-09-14 | Medtronic, Inc. | Intraluminal stent |
DE69719237T2 (en) * | 1996-05-23 | 2003-11-27 | Samsung Electronics Co Ltd | Flexible, self-expandable stent and method for its manufacture |
US5755682A (en) * | 1996-08-13 | 1998-05-26 | Heartstent Corporation | Method and apparatus for performing coronary artery bypass surgery |
WO1998012990A1 (en) | 1996-09-26 | 1998-04-02 | Scimed Life Systems, Inc. | Support structure/membrane composite medical device |
US5824046A (en) * | 1996-09-27 | 1998-10-20 | Scimed Life Systems, Inc. | Covered stent |
US5925074A (en) * | 1996-12-03 | 1999-07-20 | Atrium Medical Corporation | Vascular endoprosthesis and method |
US5897587A (en) | 1996-12-03 | 1999-04-27 | Atrium Medical Corporation | Multi-stage prosthesis |
US5824050A (en) * | 1996-12-03 | 1998-10-20 | Atrium Medical Corporation | Prosthesis with in-wall modulation |
US6010529A (en) * | 1996-12-03 | 2000-01-04 | Atrium Medical Corporation | Expandable shielded vessel support |
US6416537B1 (en) | 1996-12-03 | 2002-07-09 | Atrium Medical Corporation | Multi-stage prosthesis |
EP2298241A3 (en) * | 1996-12-03 | 2011-11-02 | Atrium Medical Corporation | Multi-stage prothesis |
US6551350B1 (en) | 1996-12-23 | 2003-04-22 | Gore Enterprise Holdings, Inc. | Kink resistant bifurcated prosthesis |
US6352561B1 (en) * | 1996-12-23 | 2002-03-05 | W. L. Gore & Associates | Implant deployment apparatus |
US6494904B1 (en) * | 1996-12-27 | 2002-12-17 | Ramus Medical Technologies | Method and apparatus for forming vascular prostheses |
US5925061A (en) * | 1997-01-13 | 1999-07-20 | Gore Enterprise Holdings, Inc. | Low profile vascular stent |
US5858556A (en) * | 1997-01-21 | 1999-01-12 | Uti Corporation | Multilayer composite tubular structure and method of making |
ATE287679T1 (en) | 1997-03-05 | 2005-02-15 | Boston Scient Ltd | COMPLIANT MULTI-LAYER STENT DEVICE |
US6077217A (en) * | 1997-06-25 | 2000-06-20 | Ramus Medical Technologies, Inc. | System and method for assembling graft structures |
US6070589A (en) | 1997-08-01 | 2000-06-06 | Teramed, Inc. | Methods for deploying bypass graft stents |
US5897911A (en) * | 1997-08-11 | 1999-04-27 | Advanced Cardiovascular Systems, Inc. | Polymer-coated stent structure |
US5931865A (en) * | 1997-11-24 | 1999-08-03 | Gore Enterprise Holdings, Inc. | Multiple-layered leak resistant tube |
US6395019B2 (en) * | 1998-02-09 | 2002-05-28 | Trivascular, Inc. | Endovascular graft |
US6488701B1 (en) | 1998-03-31 | 2002-12-03 | Medtronic Ave, Inc. | Stent-graft assembly with thin-walled graft component and method of manufacture |
US6290731B1 (en) | 1998-03-30 | 2001-09-18 | Cordis Corporation | Aortic graft having a precursor gasket for repairing an abdominal aortic aneurysm |
US6656215B1 (en) | 2000-11-16 | 2003-12-02 | Cordis Corporation | Stent graft having an improved means for attaching a stent to a graft |
US6887268B2 (en) | 1998-03-30 | 2005-05-03 | Cordis Corporation | Extension prosthesis for an arterial repair |
US6099559A (en) * | 1998-05-28 | 2000-08-08 | Medtronic Ave, Inc. | Endoluminal support assembly with capped ends |
US6066169A (en) * | 1998-06-02 | 2000-05-23 | Ave Connaught | Expandable stent having articulated connecting rods |
US6156064A (en) * | 1998-08-14 | 2000-12-05 | Schneider (Usa) Inc | Stent-graft-membrane and method of making the same |
US6143022A (en) * | 1998-08-24 | 2000-11-07 | Medtronic Ave, Inc. | Stent-graft assembly with dual configuration graft component and method of manufacture |
US6547814B2 (en) | 1998-09-30 | 2003-04-15 | Impra, Inc. | Selective adherence of stent-graft coverings |
ES2274640T3 (en) | 1998-09-30 | 2007-05-16 | Bard Peripheral Vascular, Inc. | STENT GRAY ADJUSTMENT COVER, MANDRILE AND MANUFACTURING PROCEDURE OF THIS STENT GRAFT DEVICE DEVICE. |
GB9828696D0 (en) | 1998-12-29 | 1999-02-17 | Houston J G | Blood-flow tubing |
US6350277B1 (en) | 1999-01-15 | 2002-02-26 | Scimed Life Systems, Inc. | Stents with temporary retaining bands |
US6517571B1 (en) | 1999-01-22 | 2003-02-11 | Gore Enterprise Holdings, Inc. | Vascular graft with improved flow surfaces |
US6398803B1 (en) * | 1999-02-02 | 2002-06-04 | Impra, Inc., A Subsidiary Of C.R. Bard, Inc. | Partial encapsulation of stents |
AU4606600A (en) * | 1999-05-07 | 2000-11-21 | Salviac Limited | Biostability of polymeric structures |
US6673103B1 (en) * | 1999-05-20 | 2004-01-06 | Scimed Life Systems, Inc. | Mesh and stent for increased flexibility |
US6245100B1 (en) | 2000-02-01 | 2001-06-12 | Cordis Corporation | Method for making a self-expanding stent-graft |
US6296661B1 (en) | 2000-02-01 | 2001-10-02 | Luis A. Davila | Self-expanding stent-graft |
US6821295B1 (en) | 2000-06-26 | 2004-11-23 | Thoratec Corporation | Flared coronary artery bypass grafts |
ES2257436T3 (en) * | 2000-08-23 | 2006-08-01 | Thoratec Corporation | VASCULATOR IMPLANTS COVERED AND USE PROCEDURES. |
AU2001286731A1 (en) * | 2000-08-25 | 2002-03-04 | Kensey Nash Corporation | Covered stents, systems for deploying covered stents |
US7314483B2 (en) | 2000-11-16 | 2008-01-01 | Cordis Corp. | Stent graft with branch leg |
US6942692B2 (en) | 2000-11-16 | 2005-09-13 | Cordis Corporation | Supra-renal prosthesis and renal artery bypass |
US6843802B1 (en) | 2000-11-16 | 2005-01-18 | Cordis Corporation | Delivery apparatus for a self expanding retractable stent |
US7267685B2 (en) | 2000-11-16 | 2007-09-11 | Cordis Corporation | Bilateral extension prosthesis and method of delivery |
US7229472B2 (en) | 2000-11-16 | 2007-06-12 | Cordis Corporation | Thoracic aneurysm repair prosthesis and system |
WO2002074189A2 (en) * | 2001-03-20 | 2002-09-26 | Nicast Ltd. | Electrospinning nonwoven materials with rotating electrode |
EP1372531A2 (en) * | 2001-03-30 | 2004-01-02 | Terumo Kabushiki Kaisha | Stent cover and stent |
US7201940B1 (en) | 2001-06-12 | 2007-04-10 | Advanced Cardiovascular Systems, Inc. | Method and apparatus for thermal spray processing of medical devices |
US7022135B2 (en) * | 2001-08-17 | 2006-04-04 | Medtronic, Inc. | Film with highly porous vascular graft prostheses |
US20040111108A1 (en) | 2001-11-09 | 2004-06-10 | Farnan Robert C. | Balloon catheter with non-deployable stent |
ES2320742T3 (en) | 2001-11-09 | 2009-05-28 | Angioscore, Inc. | BALL CATHETER WITH NON-DISPLAYABLE ENDOPROTESIS. |
GB2369797B (en) * | 2001-11-20 | 2002-11-06 | Tayside Flow Technologies Ltd | Helical formations in tubes |
US6752827B2 (en) * | 2001-12-04 | 2004-06-22 | Vasca, Inc. | Devices, systems, and methods for subcutaneously placing an article |
US6752826B2 (en) | 2001-12-14 | 2004-06-22 | Thoratec Corporation | Layered stent-graft and methods of making the same |
US7125464B2 (en) | 2001-12-20 | 2006-10-24 | Boston Scientific Santa Rosa Corp. | Method for manufacturing an endovascular graft section |
US7090693B1 (en) | 2001-12-20 | 2006-08-15 | Boston Scientific Santa Rosa Corp. | Endovascular graft joint and method for manufacture |
US6776604B1 (en) * | 2001-12-20 | 2004-08-17 | Trivascular, Inc. | Method and apparatus for shape forming endovascular graft material |
US7326237B2 (en) | 2002-01-08 | 2008-02-05 | Cordis Corporation | Supra-renal anchoring prosthesis |
WO2003066118A1 (en) * | 2002-02-05 | 2003-08-14 | Thoratec Corporation | Coated vascular prosthesis and methods of manufacture and use. |
US7288111B1 (en) | 2002-03-26 | 2007-10-30 | Thoratec Corporation | Flexible stent and method of making the same |
US7147647B2 (en) * | 2002-04-26 | 2006-12-12 | Medtronic, Inc. | Sintered titanium tube for the management of spinal cord injury |
DE10219014A1 (en) * | 2002-04-27 | 2003-11-13 | Ruesch Willy Gmbh | Self-expanding stent for reinforcing and/or keeping open a hollow organ comprise two elastic tubular layers which bracket and positionally fix at least one helical filament |
AU2003225291A1 (en) * | 2002-05-10 | 2003-11-11 | Cordis Corporation | Method of making a medical device having a thin wall tubular membrane over a structural frame |
WO2004026183A2 (en) | 2002-09-20 | 2004-04-01 | Nellix, Inc. | Stent-graft with positioning anchor |
US8080026B2 (en) | 2003-01-21 | 2011-12-20 | Angioscore, Inc. | Apparatus and methods for treating hardened vascular lesions |
US7686824B2 (en) * | 2003-01-21 | 2010-03-30 | Angioscore, Inc. | Apparatus and methods for treating hardened vascular lesions |
EP1590018B1 (en) * | 2003-01-28 | 2012-09-26 | Gambro Lundia AB | An apparatus for monitoring a vascular access of a patient |
EP2292183B1 (en) | 2003-03-18 | 2017-10-25 | Veryan Medical Limited | Helical balloon with stent |
AU2004222495A1 (en) * | 2003-03-18 | 2004-09-30 | Veryan Medical Limited | Helical graft |
GB0306176D0 (en) | 2003-03-18 | 2003-04-23 | Imp College Innovations Ltd | Tubing |
US20040254628A1 (en) | 2003-06-13 | 2004-12-16 | Patrice Nazzaro | One-branch stent-graft for bifurcated lumens |
GB0315714D0 (en) * | 2003-07-04 | 2003-08-13 | Tayside Flow Technologies Ltd | An internal formation for a conduit |
US20050060020A1 (en) * | 2003-09-17 | 2005-03-17 | Scimed Life Systems, Inc. | Covered stent with biologically active material |
ATE440564T1 (en) * | 2003-10-10 | 2009-09-15 | Cleveland Clinic Foundation | ENDOLUMINAL PROSTHESIS WITH CONNECTABLE MODULES |
WO2005065578A2 (en) * | 2004-01-06 | 2005-07-21 | Nicast Ltd. | Vascular prosthesis with anastomotic member |
GB0402736D0 (en) * | 2004-02-06 | 2004-03-10 | Tayside Flow Technologies Ltd | A drug delivery device |
US20050220835A1 (en) * | 2004-03-30 | 2005-10-06 | Jayaraman Ramesh B | Agent eluting bioimplantable devices and polymer systems for their preparation |
US7758654B2 (en) * | 2004-05-20 | 2010-07-20 | Kensey Nash Corporation | Anti-adhesion device |
US7297158B2 (en) * | 2004-06-14 | 2007-11-20 | Thoratec Corporation | Multilayer composite vascular access graft |
US7727271B2 (en) * | 2004-06-24 | 2010-06-01 | Boston Scientific Scimed, Inc. | Implantable prosthesis having reinforced attachment sites |
US8048145B2 (en) | 2004-07-22 | 2011-11-01 | Endologix, Inc. | Graft systems having filling structures supported by scaffolds and methods for their use |
EP1791496B1 (en) * | 2004-08-31 | 2019-07-31 | C.R. Bard, Inc. | Self-sealing ptfe graft with kink resistance |
US8029563B2 (en) | 2004-11-29 | 2011-10-04 | Gore Enterprise Holdings, Inc. | Implantable devices with reduced needle puncture site leakage |
CN101573086A (en) * | 2005-02-17 | 2009-11-04 | 尼卡斯特有限公司 | Inflatable medical device |
US7947207B2 (en) | 2005-04-12 | 2011-05-24 | Abbott Cardiovascular Systems Inc. | Method for retaining a vascular stent on a catheter |
US10076641B2 (en) | 2005-05-11 | 2018-09-18 | The Spectranetics Corporation | Methods and systems for delivering substances into luminal walls |
JP2009501027A (en) * | 2005-06-17 | 2009-01-15 | シー・アール・バード・インコーポレイテツド | Vascular graft with kinking resistance after tightening |
US7666220B2 (en) | 2005-07-07 | 2010-02-23 | Nellix, Inc. | System and methods for endovascular aneurysm treatment |
US8187318B2 (en) | 2005-08-31 | 2012-05-29 | Advanced Bio Prosthetic Surfaces, Ltd. | Covered stent with proximal and distal attachment, delivery catheter, and method of making same |
US7670369B2 (en) * | 2005-10-13 | 2010-03-02 | Cook Incorporated | Endoluminal prosthesis |
US8636794B2 (en) * | 2005-11-09 | 2014-01-28 | C. R. Bard, Inc. | Grafts and stent grafts having a radiopaque marker |
JP2009514656A (en) * | 2005-11-09 | 2009-04-09 | シー・アール・バード・インコーポレーテッド | Graft and stent graft with radiopaque beading |
US20070150041A1 (en) * | 2005-12-22 | 2007-06-28 | Nellix, Inc. | Methods and systems for aneurysm treatment using filling structures |
WO2007089500A2 (en) * | 2006-01-30 | 2007-08-09 | Pong-Jeu Lu | Dual-pulsation bi-ventricular assist device |
WO2007098234A2 (en) * | 2006-02-21 | 2007-08-30 | Med Institute, Inc. | Graft material for prostheses |
US9198749B2 (en) * | 2006-10-12 | 2015-12-01 | C. R. Bard, Inc. | Vascular grafts with multiple channels and methods for making |
US8231929B2 (en) | 2006-11-09 | 2012-07-31 | Cook Medical Technologies Llc | Medical device coating process |
US9474833B2 (en) * | 2006-12-18 | 2016-10-25 | Cook Medical Technologies Llc | Stent graft with releasable therapeutic agent and soluble coating |
US8663309B2 (en) | 2007-09-26 | 2014-03-04 | Trivascular, Inc. | Asymmetric stent apparatus and method |
US8066755B2 (en) | 2007-09-26 | 2011-11-29 | Trivascular, Inc. | System and method of pivoted stent deployment |
US20090082845A1 (en) * | 2007-09-26 | 2009-03-26 | Boston Scientific Corporation | Alignment stent apparatus and method |
US8226701B2 (en) | 2007-09-26 | 2012-07-24 | Trivascular, Inc. | Stent and delivery system for deployment thereof |
EP2194921B1 (en) * | 2007-10-04 | 2018-08-29 | TriVascular, Inc. | Modular vascular graft for low profile percutaneous delivery |
US20090105687A1 (en) * | 2007-10-05 | 2009-04-23 | Angioscore, Inc. | Scoring catheter with drug delivery membrane |
US8328861B2 (en) | 2007-11-16 | 2012-12-11 | Trivascular, Inc. | Delivery system and method for bifurcated graft |
US8083789B2 (en) | 2007-11-16 | 2011-12-27 | Trivascular, Inc. | Securement assembly and method for expandable endovascular device |
US20090171451A1 (en) * | 2007-12-27 | 2009-07-02 | Cook Incorporated | Implantable device having composite weave |
US8196279B2 (en) | 2008-02-27 | 2012-06-12 | C. R. Bard, Inc. | Stent-graft covering process |
AU2009240419A1 (en) | 2008-04-25 | 2009-10-29 | Nellix, Inc. | Stent graft delivery system |
CA2726596A1 (en) * | 2008-06-04 | 2009-12-10 | Nellix, Inc. | Sealing apparatus and methods of use |
US9597214B2 (en) | 2008-10-10 | 2017-03-21 | Kevin Heraty | Medical device |
US20100114293A1 (en) * | 2008-10-31 | 2010-05-06 | Vioptix, Inc. | Multibranch Vessel Extender |
US20100114292A1 (en) * | 2008-10-31 | 2010-05-06 | Vioptix, Inc. | Vessel Extender |
US8523756B2 (en) * | 2008-12-31 | 2013-09-03 | National Cheng Kung University | Cardiac compression system |
US20110276078A1 (en) * | 2009-12-30 | 2011-11-10 | Nellix, Inc. | Filling structure for a graft system and methods of use |
EP2380604A1 (en) | 2010-04-19 | 2011-10-26 | InnoRa Gmbh | Improved coating formulations for scoring or cutting balloon catheters |
US8632559B2 (en) | 2010-09-21 | 2014-01-21 | Angioscore, Inc. | Method and system for treating valve stenosis |
US8801768B2 (en) | 2011-01-21 | 2014-08-12 | Endologix, Inc. | Graft systems having semi-permeable filling structures and methods for their use |
AU2012231150A1 (en) | 2011-03-18 | 2013-09-19 | Marine Polymer Technologies, Inc. | Methods and apparatus for a manual radial artery compression device |
WO2012139054A1 (en) | 2011-04-06 | 2012-10-11 | Endologix, Inc. | Method and system for endovascular aneurysm treatment |
US8992595B2 (en) | 2012-04-04 | 2015-03-31 | Trivascular, Inc. | Durable stent graft with tapered struts and stable delivery methods and devices |
US9498363B2 (en) | 2012-04-06 | 2016-11-22 | Trivascular, Inc. | Delivery catheter for endovascular device |
BR112015022688B1 (en) | 2013-03-14 | 2020-10-06 | Endologix, Inc. | METHOD FOR FORMING A MATERIAL IN SITU THROUGH INCREASING THE VOLUME OF AN EXPANDABLE MEMBER OF A MEDICAL DEVICE |
US10117668B2 (en) | 2013-10-08 | 2018-11-06 | The Spectranetics Corporation | Balloon catheter with non-deployable stent having improved stability |
US9814560B2 (en) | 2013-12-05 | 2017-11-14 | W. L. Gore & Associates, Inc. | Tapered implantable device and methods for making such devices |
CN103720529B (en) * | 2013-12-30 | 2017-02-08 | 先健科技(深圳)有限公司 | Arcus aortae intraoperative stent and method for manufacturing stent |
CN110946684B (en) | 2015-06-05 | 2022-06-03 | W.L.戈尔及同仁股份有限公司 | Hypotonic blood volume implantable prosthesis with tapered portion |
WO2017189364A1 (en) | 2016-04-25 | 2017-11-02 | Solinas Medical, Inc. | Self-sealing tubular grafts, patches, and methods for making and using them |
WO2018039651A1 (en) * | 2016-08-26 | 2018-03-01 | Healionics Corporation | Corrugated microporous tissue interface for improved performance and infection resistance of vascular grafts and other implantable devices |
CN106540327A (en) * | 2016-12-06 | 2017-03-29 | 北京航空航天大学 | A kind of three layers of artificial blood vessel bracket of imitative nature blood vessel and preparation method thereof |
EP3391852A3 (en) * | 2017-04-21 | 2018-11-14 | Cook Medical Technologies LLC | Reinforced graft prosthesis |
US10575973B2 (en) | 2018-04-11 | 2020-03-03 | Abbott Cardiovascular Systems Inc. | Intravascular stent having high fatigue performance |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL127872C (en) * | 1965-03-19 | |||
US3511684A (en) * | 1967-05-17 | 1970-05-12 | Abbott Lab | Method of treating polymeric resin to display nonthrombogenicity |
DE2017330A1 (en) * | 1970-04-10 | 1971-12-09 | BIO-CAL Instrument GmbH, 8032 Gräfelfing | Blood vessel connector - for artificial kidneys or lungs |
US3730835A (en) * | 1971-04-15 | 1973-05-01 | Alza Corp | Novel device coated with a prosta-glandin and preparation thereof |
JPS6011054B2 (en) * | 1975-03-28 | 1985-03-22 | ダブリユー・アール・グレース・アンド・カンパニー | Method for manufacturing dental or medical foam |
CA1092303A (en) * | 1976-05-05 | 1980-12-30 | David C. Macgregor | Flexible vascular graft of polymeric material with internal porous surface |
US4101984A (en) * | 1975-05-09 | 1978-07-25 | Macgregor David C | Cardiovascular prosthetic devices and implants with porous systems |
US4281669A (en) * | 1975-05-09 | 1981-08-04 | Macgregor David C | Pacemaker electrode with porous system |
CA1068052A (en) * | 1975-12-22 | 1979-12-18 | David C. Macgregor | Prosthetic devices and implants with porous systems in a soft tissue environment |
US4173689A (en) * | 1976-02-03 | 1979-11-06 | University Of Utah | Synthetic polymer prosthesis material |
US4130904A (en) * | 1977-06-06 | 1978-12-26 | Thermo Electron Corporation | Prosthetic blood conduit |
JPS5413694A (en) * | 1977-07-01 | 1979-02-01 | Sumitomo Electric Industries | Composite blood vessel prosthesis and method of producing same |
JPS5438439A (en) * | 1977-08-30 | 1979-03-23 | Agency Of Ind Science & Technol | Fuel injection for pump multiple injection |
CH632921A5 (en) * | 1978-04-06 | 1982-11-15 | Intermedicat Gmbh | Method of producing bend-free, elastic, puncture-tight vascular protheses |
JPS54135493A (en) * | 1978-04-13 | 1979-10-20 | Asahi Chemical Ind | Medical urethane resin |
DE2929246C3 (en) * | 1978-07-21 | 1981-09-17 | Intermedicat GmbH, Emmenbrücke | Process for the production of small-caliber vascular prostheses from a combination of different plastics |
JPS5519607A (en) * | 1978-07-24 | 1980-02-12 | Daido Kogyo Co Ltd | Casting wheel in light alloy |
JPS6037734B2 (en) * | 1978-10-12 | 1985-08-28 | 住友電気工業株式会社 | Tubular organ prosthesis material and its manufacturing method |
JPS6037735B2 (en) * | 1978-10-18 | 1985-08-28 | 住友電気工業株式会社 | Artificial blood vessel |
US4286341A (en) * | 1979-04-16 | 1981-09-01 | Iowa State University Research Foundation, Inc. | Vascular prosthesis and method of making the same |
JPS5588760A (en) * | 1979-10-25 | 1980-07-04 | Hiroshi Matsumoto | Artificial blood vessel |
DE3019996A1 (en) * | 1980-05-24 | 1981-12-03 | Institute für Textil- und Faserforschung Stuttgart, 7410 Reutlingen | HOHLORGAN |
-
1981
- 1981-02-13 US US06/234,116 patent/US4604762A/en not_active Expired - Lifetime
-
1982
- 1982-02-10 GB GB8203810A patent/GB2092894B/en not_active Expired
- 1982-02-11 DE DE19823204719 patent/DE3204719A1/en not_active Ceased
- 1982-02-12 CA CA000396176A patent/CA1207105A/en not_active Expired
- 1982-02-12 JP JP57021007A patent/JPS57150954A/en active Pending
- 1982-02-12 FR FR8202307A patent/FR2499847B1/en not_active Expired
-
1984
- 1984-05-21 US US06/612,997 patent/US4731073A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DE3204719A1 (en) | 1982-09-16 |
JPS57150954A (en) | 1982-09-17 |
FR2499847B1 (en) | 1987-01-09 |
GB2092894A (en) | 1982-08-25 |
US4731073A (en) | 1988-03-15 |
GB2092894B (en) | 1985-03-13 |
US4604762A (en) | 1986-08-12 |
FR2499847A1 (en) | 1982-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1207105A (en) | Arterial graft prosthesis | |
US6821295B1 (en) | Flared coronary artery bypass grafts | |
US5866217A (en) | Silicone composite vascular graft | |
US4300244A (en) | Cardiovascular grafts | |
EP0656196B1 (en) | Implantable tubular prosthesis | |
US5383927A (en) | Non-thromogenic vascular prosthesis | |
EP0157178B1 (en) | Artificial vessel and process for preparing the same | |
US4850999A (en) | Flexible hollow organ | |
EP0216149B1 (en) | Artificial vessel having excellent patency | |
US4804382A (en) | Artificial vessel | |
JP2739878B2 (en) | Reinforced implant assembly and method of making the same | |
JP2002540854A (en) | Pipe lining | |
JPH07178124A (en) | Built-in type artificial organ | |
JP2003514578A (en) | Spider silk covered stent | |
US4986832A (en) | Artificial blood vessel and process for preparing it | |
JP4187986B2 (en) | Medical tubular body and method for producing the same | |
US4871361A (en) | Artificial vessel | |
RU2117459C1 (en) | Implanted hollow prosthesis | |
JPH06189984A (en) | Artificial blood vessel and manufacture thereof | |
JPS602257A (en) | New artificial blood vessel | |
JPS60188164A (en) | Artifical vessel | |
JPS61238238A (en) | Production of artificial blood vessel | |
RU2774590C1 (en) | Implantable hollow prosthesis and method of forming framework | |
CA1092303A (en) | Flexible vascular graft of polymeric material with internal porous surface | |
RU211664U1 (en) | HOLLOW IMPLANTABLE PROSTHESIS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKEX | Expiry |